Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
28.34
-1.52 (-5.09%)
At close: May 30, 2025, 4:00 PM
29.99
+1.65 (5.82%)
After-hours: May 30, 2025, 7:55 PM EDT

Company Description

Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases.

It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis.

Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency.

Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Sugar Land, Texas.

Tvardi Therapeutics, Inc.
Tvardi Therapeutics logo
Country United States
Founded 2017
Industry Biotechnology
Sector Healthcare
CEO Imran Alibhai

Contact Details

Address:
3 Sugar Creek Center Boulevard, Suite 525
Sugar Land, Texas 77478
United States
Phone 832-413-1362
Website tvarditherapeutics.com

Stock Details

Ticker Symbol TVRD
Exchange NASDAQ
Stock Type Common Stock
Reporting Currency USD
CIK Code 0001742947
CUSIP Number 140755307
ISIN Number US1407553072

Key Executives

Name Position
Dr. Imran Alibhai Ph.D. Chief Executive Officer and Director
Wallace Hall Jr. Founder, President and Director
David J. Tweardy M.D. Co-Founder and Scientific Advisory Board Member
Dr. Ronald A. DePinho M.D. Co-Founder and Chairman of Scientific Advisory Board
Dr. Michael T. Lewis Ph.D. Co-Founder and Scientific Advisory Board Member
Dan Conn J.D., M.B.A. Chief Financial Officer
Dr. Jeffrey Larson DABT, Ph.D. Senior Vice President of Research & Development
Dr. John Kauh M.D. Chief Medical Officer
Stephen O'Brien CPA Vice President of Finance and Corporate Controller
Dr. Yixin Chen Ph.D. Vice President of CMC